Omeros' MASP-2 program has been focused on the development of antibodies that target MASP-2 and its unique role in the activation of the lectin pathway. The Company has conducted a series of in ...

The lectin pathway is homologous to the classical pathway, but with the opsonin, mannose-binding lectin (MBL) and ficolins, instead of C1q. The FDA has now approved seven indications for ...

Plus, it has to be taken every day subcutaneously. On the other hand, DNTH103 avoids targeting the lectin [C5 inhibition seen here] and alternative pathways [c3a, c35a and other pathways seen here].

In addition to its lectin pathway inhibitors, the company is advancing its development of antibodies and small-molecule inhibitors against MASP-3 to block activation of the alternative pathway.

The lectin pathway is the third pathway in the complement cascade, discovered after the classical and alternative pathways. It more closely resembles the classical pathway due to similar binding ...

Omeros also has identified MASP-3 as responsible for the conversion of pro-factor D to factor D and as a critical activator of the human complement system’s alternative pathway.

OMS721 selectively inhibits MASP-2, blocking the lectin pathway of the complement system while leaving intact the classical pathway, or the acquired immune response to infection.

Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative ...

Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative ...

Complement C1q is classical complement and is involved in activation of macrophages, said Lally. "In preclinical studies, I'm not aware of any side effects," he said. "That's different from ...